10° Simposio medico annuale ECD Barcellona, Spagna
Immagine di gruppo del Simposio Medico di Barcellona 2025
Sintesi del simposio
Circa 54 professionisti medici provenienti da 8 paesi hanno partecipato al Simposio Medico Annuale sulla ECD nel 2025. Sono stati presentati diciotto abstract orali, insieme ad altre 8 presentazioni di poster. In qualità di relatore ospite, il dottor Manel Juan ha tenuto un intervento dal titolo “Immunoterapie con cellule CAR-T: guidare le terapie oltre i tumori ematologici, attraverso il modello Barcellona”. Un ricevimento serale ha permesso di discutere di collaborazioni attuali e future tra questo gruppo di medici e scienziati altamente qualificati, tutti interessati a saperne di più sulla malattia di Erdheim-Chester.
Programmi con l’agenda del simposio
Agenda
| Presenter | Presentation Title & Slides | Video |
|---|---|---|
| Xavier Solanich, Paul Hendrie | Welcome to Barcelona and the 10th Annual Erdheim-Chester Disease International Conference | Watch (1) Watch (2) |
| Manel Juan | CAR-T-cell Immunoherapies: driving therapies beyond Hematological Cancers, through the Barcelona model. | Watch |
| Oshrat Hershkovitz-Rokah | Advanced proteomic profiling for biomarker discovery in Erdheim-Chester Disease | Watch |
| Benjamin Durham | RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition | Watch |
| Julien Haroche | BCL-2 immunohistochemistry expression in patients with histiocytosis | Watch |
| Lindsay Hill | Comparative Genetic Analysis of Primary versus Secondary Histiocytic Sarcoma: A Single Institution Case Series | Watch |
| Carla Isabel Borre | Comparative Efficacy of Frontline Targeted Therapies Versus Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | Watch |
| Francesco Pegoraro | Second cancer in Erdheim-Chester disease | Watch |
| Jerome Razanamahery | Glomeruloid angioma in Erdheim-Chester disease: an atypical skin manifestation associated with elevated VEGF-A | Watch |
| Francesco Catamerò | Treatment Holidays in Patients with Erdheim-Chester Disease Receiving Vemurafenib: A Prospective Pilot Study | Watch |
| Brinda Shukla | Don’t Dish Out Old Therapies: Use of Pegylated-Interferon-Alpha in a case of Erdheim-Chester Disease with congestive heart failure | Watch |
| Eli Diamond | Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: A longitudinal registry-based analysis | Watch |
| Pudis Michal | Diagnostic Impact of 18F-FDG PET/MRI over PET/CT in Histiocytoses: A Prospective Comparative Study | Watch |
| Francesco Pegoraro | Natural history of Erdheim-Chester disease. A preliminary analysis on 1044 patients within the ECDGA network | Watch |
| Mia Poleksic | Erdheim-Chester Disease: Evolving Insights and Improved Survival Over Time | Watch |
| Gaurav Goyal | Real-World Efficacy and Toxicity of MEK Inhibitors in Histiocytic Neoplasms | Watch |
| Jerome Razanamahery | MAPK-kinase mutations and aortic lesions are associated with the distribution of circulating monocytes in histiocytosis | Watch |
| Abdou Malik Da Silva | Deciphering ALK-positive histiocytosis and mimickers using single cell RNAsequencing | Watch |
| Matthew Collin | The clonal origin and evolution of highrisk multisystem histiocytosis in adults | Watch |
| Polyzois Makras | Mapping Erdheim-Chester Disease in Europe through the Core Registry | Watch |
| Jerome Razanamahery | Layers of Complexity: ECD Diagnosis and management in the presence of confounding comorbidities Jerome Razanamahery Dijon University Hospital, Dijon, France Closing Remarks & Student Abstract | Watch |
| Diane Schriner | ECD Global Alliance into the Future | Watch |